Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

OPKO Health to Participate at Three Investment Conferences in December

Posted on: 30 Nov 16

MIAMI, Nov. 30, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), announces that its senior management team will host one-on-one investor meetings with institutional investors participating at the following investor conferences in December:

  • Evercore ISI MedTools Investor Conference taking place November 30-December 1, 2016 at the Boston Harbor Hotel;
  • Citi 2016 Global Healthcare Conference taking place December 7-8, 2016 at the Lott New York Palace in New York City;
  • Guggenheim Securities 4th Annual Boston Healthcare Conference taking place on December 13, 2016 at The InterContinental Boston.

Attendance at these conferences is by invitation only. The investor presentation used at the conferences will be posted to the Investor Relations page of the Company's website at under “Events” on the day of the event.

Institutional investors attending these conferences who are interested in meeting with OPKO Health management should contact their representatives at Evercore ISI, Citi and/or Guggenheim Securities, respectively.

About OPKO Health, Inc.  

OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation PDUFA date: January 2017), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications.  Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in phase 2a) and a long-acting oxyntomodulin for diabetes and obesity (in phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at


Last updated on: 01/12/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.